Genotype-guided ticagrelor/prasugrel versus clopidogrel therapy in stroke patients with <i>CYP2C19</i> loss of function alleles: a systematic review and meta-analysis
TIA/IS patients inheriting <i>CYP2C19</i> LoF alleles taking ticagrelor/prasugrel may significantly optimize the overall clinical benefits compared to those who are taking clopidogrel by reducing composite vascular events and recurrent stroke without elevating the risk of bleeding events.
Authors
- Mohitosh Biswas (ORCID: https://orcid.org/0000-0003-1432-7701)
- Maliheh Ershadian
- Shahnaz Parvin Sweety
- Chonlaphat Sukasem
- Murshadul Alam Murad
- Sakib Al Hasan
Institutions
- Burapha University (TH)
- Manarat International University (BD)
- Mahidol University (TH)
- Bumrungrad International Hospital (TH)
- Ramathibodi Hospital (TH)
- University of Rajshahi (BD)
Publication Details
- Journal
- Pharmacogenomics
- Published
- 2025-11-02
- DOI
- https://doi.org/10.1080/14622416.2025.2603565
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00